{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T15:04:44Z","timestamp":1648998284818},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12185-018-2521-4","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T14:09:12Z","timestamp":1535551752000},"page":"353-354","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guest editorial: chronic myeloid leukemia"],"prefix":"10.1007","volume":"108","author":[{"given":"Yosuke","family":"Minami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,28]]},"reference":[{"key":"2521_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, et al. Deeper molecular response is an independent predictive factor for successful treatment-free remission after imatinib discontinuation in patients with chronic-phase chronic myeloid leukemia: JALSG-STIM213 Study. Int J Hematol. 2018;107:185\u201393.","journal-title":"Int J Hematol"},{"key":"2521_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2295-0","author":"D Rea","year":"2018","unstructured":"Rea D, Cayula J-M. Treatment-free remission in patients with chronic myeloid leukemia. Int J Hematol. 2018;. \n                    https:\/\/doi.org\/10.1007\/s12185-017-2295-0\n                    \n                  .","journal-title":"Int J Hematol."},{"key":"2521_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"B Ami","year":"2017","unstructured":"Ami B, Patel T, O\u2019Hare, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin N Am. 2017;31:589\u2013612.","journal-title":"Hematol Oncol Clin N Am"},{"key":"2521_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.cell.2009.08.017","volume":"138","author":"M Shackleton","year":"2009","unstructured":"Shackleton M, Quintana E, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138:822\u20139.","journal-title":"Cell"},{"key":"2521_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275\u201391.","journal-title":"Cell Stem Cell"},{"key":"2521_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506\u201310.","journal-title":"Nature"},{"key":"2521_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645\u20138.","journal-title":"Nature"},{"key":"2521_CR8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730\u20137.","journal-title":"Nat Med"},{"key":"2521_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert K, Takenaka K, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17:1086\u201393.","journal-title":"Nat Med"},{"key":"2521_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-032712-095921","volume":"31","author":"A Rongvaux","year":"2013","unstructured":"Rongvaux A, Takizawa H, Strowig T, Willinger T, Eynon EE, Flavell RA, Manz MG. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol. 2013;31:635\u201374.","journal-title":"Annu Rev Immunol"},{"key":"2521_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists. Nature. 2015;525:380\u20133.","journal-title":"Nature"},{"key":"2521_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang J, Adri\u00e1n FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. Targeting Bcr\u2013Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010;463:501\u20136.","journal-title":"Nature"},{"key":"2521_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature. 2017;543:733\u20137.","journal-title":"Nature"},{"key":"2521_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2519","author":"A Inoue","year":"2018","unstructured":"Inoue A, Kobayashi CI, et al. Chronic myeloid leukemia stem cells and molecular target therapies forovercoming resistance and disease persistence. Int J Hematol. 2018;. \n                    https:\/\/doi.org\/10.1007\/s12185-018-2519\n                    \n                  .","journal-title":"Int J Hematol."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2521-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T23:19:15Z","timestamp":1566947955000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2521-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,28]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2521-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,28]]},"assertion":[{"value":"20 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}